Physician profile
Jill Morrison
NPI 1184670952
$3,613.37
in general payments reported to CMS, 2019-2025
34 companies · $1,583 in 2025
The $1,583 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $161 · 2021: $135 · 2022: $99.69 · 2023: $493 · 2024: $997 · 2025: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,003 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,002.76 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $899.98 | 2020-2025 | Enhertu, Datroway |
| Gilead Sciences, INC. | $555.02 | 2021-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals Lp | $409.43 | 2019-2025 | Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $195.79 | 2020-2025 | |
| Pfizer INC. | $172.49 | 2020-2025 | |
| Depuy Synthes Sales INC. | $154.33 | 2024 | Trumatch |
| Janssen Biotech, INC. | $138.62 | 2019-2025 | Imbruvica, Erleada, Darzalex |
| Merck Sharp & Dohme LLC | $122.98 | 2019-2025 | Keytruda, Reblozyl, Welireg |
| Tempus Ai, INC | $106.90 | 2024-2025 | Xt Cdx |
| Incyte Corporation | $105.66 | 2019-2025 | Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $70.26 | 2020-2025 | |
| Lilly USA, LLC | $68.86 | 2022-2025 | Verzenio, Jaypirca |
| Celgene Corporation | $59.59 | 2021-2024 | Pomalyst |
| Glaxosmithkline, LLC. | $49.79 | 2025 | Ojjaara |
| Myriad Genetic Laboratories, INC. | $48.34 | 2023 | Precisetumor |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $46.85 | 2020-2023 | Reblozyl, Opdualag |
| Genentech USA, INC. | $43.17 | 2024-2025 | Itovebi, Polivy, Columvi |
| Genzyme Corporation | $41.46 | 2020-2023 | |
| Alexion Pharmaceuticals, INC. | $32.87 | 2024-2025 | Ultomiris |
| Stemline Therapeutics INC. | $32.59 | 2025 | Orserdu |
| Abbvie INC. | $30.82 | 2025 | |
| Novocure INC. | $28.43 | 2024 | Optune |
| Exelixis INC. | $22.63 | 2024 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $20.71 | 2025 | Iclusig |
| Tersera Therapeutics LLC | $19.94 | 2023 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $18.10 | 2025 | Onivyde |
| Geron Corporation | $16.98 | 2025 | Rytelo |
| Aadi Bioscience, INC. | $16.81 | 2024 | Fyarro |
| Veloxis Pharmaceuticals, INC. | $16.77 | 2023 | Envarsus |
| Emd Serono, INC. | $14.87 | 2019 | |
| Eisai INC. | $14.85 | 2019 | |
| Curium US LLC | $13.25 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.14 | 2022 | |
| Adc Therapeutics America, INC. | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.